Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-Biliary01: Rilvegostomig + Chemotherapy as Adjuvant Treatment for Biliary Tract Cancer
NCT06109779Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2023
- Primary completion
- Jan 2029
- Countries
- 21
01
Overview
A Phase 3 trial of rilvegostomig in biliary tract cancer (BTC), sponsored by AstraZeneca. Started Dec 2023; status: active, not recruiting.
02
Drugs
rilvegostomig
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06109779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06109779.